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Introduction
Autophagy is required for cellular homeostasis, and perturba-
tions in the process can lead to a variety of diseases, includ-
ing neurodegeneration, impaired immunity and cancer.1-5 The 
molecular mechanism of autophagy is conserved from yeast to 
humans and has been well characterized.6 During autophagy, 
double-membraned vesicles termed autophagosomes engulf 
and transport cytoplasmic contents such as protein aggregates, 
pathogens and damaged mitochondria to lysosomes for degrada-
tion. Despite our relatively good understanding of the molecu-
lar mechanism of autophagy, we are only starting to learn how 
autophagy contributes to cellular responses in different contexts. 
For example, autophagy is essential for the cellular response to 
a plethora of different stresses that regulate cell viability, but in 
certain contexts this can promote cell survival, whereas in others 
it can contribute to cell death.7,8 This presents a potential diffi-
culty for using inhibitors of autophagy to treat complex diseases 
such as cancer, as the effect of inhibiting autophagy in different 
settings is difficult to predict.
Clinical trials are nonetheless underway to assess the effect of 
autophagy inhibition on cancer progression in a variety of tumors 
types, and there is evidence to show that inhibition of autophagy 
can increase survival outcomes for patients with glioblastoma 
multiforme.9 However, similar to the bipolar reports on the role 
of autophagy in cell death and cell survival, studies in vitro and 
Autophagy is a membrane-trafficking process that delivers cytoplasmic constituents to lysosomes for degradation. It 
contributes to energy and organelle homeostasis and the preservation of proteome and genome integrity. Although 
a role in cancer is unquestionable, there are conflicting reports that autophagy can be both oncogenic and tumor 
suppressive, perhaps indicating that autophagy has different roles at different stages of tumor development. In this 
report, we address the role of autophagy in a critical stage of cancer progression—tumor cell invasion. Using a glioma cell 
line containing an inducible shRNA that targets the essential autophagy gene Atg12, we show that autophagy inhibition 
does not affect cell viability, proliferation or migration but significantly reduces cellular invasion in a 3D organotypic 
model. these data indicate that autophagy may play a critical role in the benign to malignant transition that is also central 
to the initiation of metastasis.
Inhibition of autophagy impairs tumor cell 
invasion in an organotypic model
Robin L. Macintosh,1 paul timpson,1 Jacqueline thorburn,2 Kurt I. Anderson,1 Andrew thorburn2 and Kevin M. Ryan1,*
1Beatson Institute for Cancer Research; Glasgow, UK; 2Department of pharmacology; University of Colorado School of Medicine; Aurora, Co USA
Key words: autophagy, invasion, migration, cancer, organotypic model
Abbreviations: dox, doxycycline; shRNA, short-hairpin RNA; Atg, autophagy-related gene; NTC, non-targeting control; 
EBSS, Earle’s balanced salt solution; LC3, microtubule-associated protein 1 light chain 3β
in mouse models of cancer suggest that inhibition of autophagy 
may not be beneficial in all tumor types. While some studies 
show that certain tumors depend on autophagy for survival,10,11 
deletion of autophagy genes has also revealed tumor suppressive 
effects.12-15 These seemingly contradictory reports may indicate 
that autophagy is pro- or anti-tumorogenic depending on the 
context or the stage of tumor development.
The development of cancer is a multi-stage process.16 In the 
initial stages of tumor development, the capacity to replicate 
beyond normal constraints and the ability to evade programmed 
cell death pathways are key events.16 As tumors develop and 
grow, tumor cells need to invade local tissue, survive upon tissue 
detachment and acquire the characteristics needed to form a sec-
ondary mass at a distant site.16 Although the role of autophagy in 
controlling programmed cell death has been heavily investigated, 
the role of autophagy in these other tumor cell attributes is poorly 
understood. We report here a study to analyze the role played by 
autophagy in tumor cell invasion using a 3D organotypic model 
designed to mimic in vivo interactions between invasive cells and 
the surrounding stroma.17 Using cells containing a doxycycline-
regulated shRNA against a key component of the autophagy 
machinery, Atg12, we show that inhibition of autophagy impairs 
tumor cell invasion in an organotypic model. We consider, there-
fore, that these findings indicate that autophagy may be required 
for this key characteristic of tumor cells as they progress toward 
malignant disease.© 2012 Landes Bioscience.
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Figure 1. Atg12 knockdown inhibits basal autophagy and starvation induced autophagy. Where indicated GL261 shAtg12 cells (A) and NtC cells (B) 
were cultured with doxycycline for 72 h to induce shRNA expression. Cells were then starved for indicated time periods and the cell lysates analyzed 
by western blot. Where indicated, cells were incubated with lysosomal protease inhibitors e64d and pepstatin A for a total of 7 h including any starva-
tion period. (C–e) Cells were infected with adenovirus containing GFp-LC3 and then starved for 6 h to induce autophagy. Representative images 
(cropped 60x images) showing GFp-LC3 localization in shAtg12 cells cultured without (C) and with (D) doxycycline are shown. (e) Quantification of the 
number of cells containing GFp-LC3 puncta. Microscope images (60x objective) were taken at random positions and the percentage of cells contain-
ing more than five GFp-LC3 puncta were counted. Scale bars are 10 μm. the graph shows the mean and standard deviations from four uncropped 60x 
images per condition.
Results
RNAi-mediated knockdown of Atg12 in glioma cells impedes 
autophagy. To investigate the role of autophagy in key charac-
teristics of tumor cell behavior, we utilized a glioma cell line that 
expresses a shRNA under the control of the tetracycline-inducible 
promoter that targets the essential autophagy gene Atg12 (shAtg12 
cells). Treatment of this cell line with the tetracycline analog doxy-
cycline (Dox) induced expression of the shRNA and decreased lev-
els of Atg12 expression (Fig. 1A). In contrast, no decrease in Atg12 
levels was observed following Dox treatment of a control line con-
taining a non-targeting shRNA (NTC cells) (Fig. 1B).
To monitor the impact of decreased levels of Atg12 on autoph-
agy, we analyzed the levels of a form of the LC3 protein termed © 2012 Landes Bioscience.
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Figure 2. Cell viability and growth are unaffected by Atg12 knockdown. 
Cells were cultured in doxycycline for 9 d. (A) After 9 d, the percentage 
of apoptotic cells (cells containing less than a G1 compliment of DNA) 
was measured by flow cytometry of permeablized cells stained with 
propidium iodide. (B) the total numbers of dead/necrotic cells were 
determined by incubating unfixed cells in propidium iodide without 
permeablisation and counting the stained (permeable/dead) cells by 
flow cytometry. (C) total cell numbers over 9 d were monitored by 
counting trypsinized cells at 2, 5 and 9 d.
LC3-II18 after Dox treatment of shAtg12 cells. LC3 is encoded by 
the essential autophagy gene MAP1LC3B and, once expressed, is 
immediately cleaved into a form termed LC3-I. Upon initiation 
of autophagy, LC3-I is conjugated to the lipid phosphatidyletha-
nolamine, and this form of LC3, termed LC3-II, integrates into 
the autophagosome membrane.18 The ratio of LC3-I to LC3-II 
is a measure of autophagic activity and can be assessed based on   
differences in electrophoretic mobility, which can be discerned 
by western blotting.18,19 Treatment of shAtg12 cells with Dox 
increased the ratio of LC3-I to LC3-II compared with untreated 
shAtg12 cells (Fig. 1A), especially when cells were incubated in 
Earle’s balanced salt solution (EBSS), a medium lacking amino 
acids that induces autophagy. In contrast, Dox treatment of 
NTC cells did not affect the LC3-I/LC3-II ratio (Fig. 1B). 
These results suggest that ATG12 knockdown could impair 
the initiation of autophagy. However, LC3-II is also degraded 
by autophagy, and a reduction in the amount of LC3-II could 
potentially indicate an enhancement in autophagic degradation. 
The use of lysosomal inhibitors E64d and pepstatin A blocks the 
degradation stage of autophagy and therefore enhances accumu-
lation of LC3-II following induction of autophagy. As expected, 
incubation of shAtg12 cells in EBSS in the absence of Dox 
caused accumulation of LC3-II that was enhanced by treatment 
with E64d and pepstatin A (Fig. 1A). Conversely, the smaller 
accumulation of LC3-II seen in Dox-treated shAtg12 cells fol-
lowing incubation in EBSS was not enhanced by treatment with 
E64d and pepstatin A. This clearly indicates that ATG12 knock-
down inhibited the initiation of autophagy. Treatment of NTC 
cells with Dox had no effect on EBSS-induced accumulation of 
LC3-II either in the absence or presence of E64d and pepstatin A 
(Fig. 1B).
We also assessed if the decreased levels of LC3-II seen in 
shAtg12 cells following treatment with Dox genuinely represented 
a decrease in autophagosome number. To do this, we infected 
cells with a previously described adenovirus that expresses LC3 
fused to GFP.20 Using this virus, autophagosomes can be detected 
as distinct puncta via fluorescent microscopy. These studies 
revealed that knockdown of Atg12 by Dox treatment of shAtg12 
cells greatly impaired the accumulation of autophagosomes fol-
lowing incubation in EBSS (Fig. 1C–E). By contrast, no effect 
on autophagosome number was observed in NTC cells following 
treatment with Dox (Fig. 1E). Taken together, these data indi-
cate that shAtg12 cells constitute a robust system in which to 
investigate tumor-related cell behavior in both autophagy-com-
petent and autophagy-deficient states.
Loss of autophagy does not impair cell proliferation or cell 
viability in glioma cells. Using shAtg12 cells, we were interested 
to know if autophagy was required for several tumor-associated 
phenotypes. First, we tested if loss of autophagy following deple-
tion of Atg12 has any effect on cell viability. Cells that had been 
incubated in the absence or presence of Dox for 9 d were analyzed 
by flow cytometry for the appearance of cells with sub-G1 DNA 
content, a reliable marker of apoptotic death. As can be seen in 
Figure 2A, loss of Atg12 had no impact on the appearance of 
apoptotic cells, as the percentage of cells with a sub-G1 DNA 
content was equal to cells that had been incubated in the absence 
of Dox. Similarly, treatment of NTC cells with Dox also had no 
effect on the appearance of apoptotic cells (Fig. 2A).
In addition to apoptotic cell death, cells can also die by necro-
sis, and it has been shown that autophagy can act to repress this 
form of death. To test if loss of Atg12 has an impact on necrosis, 
cells were incubated in propidium iodide (PI), which enters per-
meabilized cells (a characteristic of necrosis), where it fluoresces 
following intercalation with DNA. Similar to what was observed 
following analysis of apoptosis, no increase in PI positivity was 
observed following Dox treatment of either shAtg12 cells or © 2012 Landes Bioscience.
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Figure 3. Cell migration velocity and persistence are unaffected by 
Atg12 knockdown. Migration of cells across a scratch wound was 
monitored by time-lapse microscopy and individual cells were tracked 
using ImageJ software. Average velocity (A) and persistence (B) are 
shown. persistence was calculated as the euclidean distance (distance 
in a straight line from start to finish) divided by the total accumulated 
distance. error bars are the standard deviation from two independent 
experiments with three images per time point for each experiment.
NTC cells, indicating that inhibition of autophagy does not lead 
to necrotic cell death (Fig. 2B).
The growth and proliferation of cells is connected to availabil-
ity of nutrients, and since autophagy is intricately connected to 
nutrient availability, we next considered whether autophagy may 
be required for another characteristic of cancer cells’ sustained 
continual replication. shAtg12 cells and NTC cells were incu-
bated in the absence or presence of Dox for a period of 9 d, while 
each cell population was assessed periodically by measuring cell 
number. This revealed that under normal growth conditions, 
the loss of Atg12, and by association the loss of autophagy, had 
no impact on proliferation as cells numbers did not significantly 
differ after 9 d of Dox treatment when compared with controls 
(Fig. 2C).
Loss of autophagy does not affect glioma cell migration, 
but impairs invasion in a 3D organotypic model. The ability of 
tumor cells to migrate and invade local tissue is a key characteristic 
of cancer and a defining transition that distinguishes benign from 
malignant growth.16 We questioned, therefore, using the shAtg12 
cell model, whether autophagy was required for these processes. 
As in previous assays, shATG12 cells (and NTC cells) were 
incubated in the absence or presence of Dox for 9 d to allow for 
generation of autophagy-competent and autophagy-deficient cells. 
These cells were then plated and when confluent were subjected 
to a “scratch assay” to measure cell migration. Cell populations 
were scratched with a plastic implement to create a wound in the 
cell monolayer. The ability of cells to fill this wound was moni-
tored by time-lapse microscopy, and parameters of cell migration 
were measured over time. As can be seen in Figure 3, the ability 
of glioma cells to migrate in response to a scratch wound was not 
affected by loss of autophagy. More detailed analysis of the data 
from this assay indicates that loss of autophagy has no impact on 
two specific parameters of migration, velocity or persistence, in 
this glioma cell model (Fig. 3A and B).
Cell migration is only one facet of invasive and metastatic 
tumor cells. In an in vivo setting, tumor cells must be able to 
invade adjacent tissue to reach local blood and lymphatic ves-
sels in order to metastasize. To examine the role of autophagy 
in this process, we utilized a previously characterized organo-
typic model of invasion involving fibroblast-contracted collagen 
matrices.17,21,22 Cells were seeded onto matrices in the absence or 
presence of Dox and incubated for 72 h to induce Atg12 knock-
down under conditions that did not promote invasion. Cells were 
then allowed to invade toward a chemoattractant (FBS) for up 
to 9 d. Treatment of shRNA Atg12 cells with Dox reduced inva-
sion by ~45% and ~25% after 7 and 9 d, respectively (Fig. 4A, B 
and E). By contrast, no significant difference in cellular inva-
sion was detected in NTC cells following treatment with Dox 
(Fig. 4C, D and F). When taken together, these results indicate 
that autophagy is required for glioma cell invasion in a manner 
independent of cell viability, cell proliferation and cell migration. 
Since autophagy is known to be deregulated in multiple tumor 
types, these findings reveal an additional function of autophagy 
that may be relevant to the benign-to-malignant conversion and 
for the establishment of metastatic disease.
Discussion
The ability of tumor cells to invade local tissue is a key character-
istic of the malignant phenotype and is a characteristic required 
for the initiation of metastasis.16 Numerous studies have indi-
cated that autophagy has roles during tumor development, and 
to the best of our knowledge, we report here for the first time that 
autophagy is important for cell invasion. We show, in an organo-
typic model involving 3D fibroblast-contracted collagen I matri-
ces, that inhibition of autophagy via RNAi-mediated knockdown 
of the essential autophagy gene Atg12 greatly impairs the invasive 
nature of glioma cells. Perhaps the most interesting aspect of our 
discovery is that inhibition of autophagy made no difference to 
several other tumor cell phenotypes in our model when measured 
in 2D. Cell death and cell growth have both been connected to 
autophagy,23-25 but inhibition of autophagy had no impact on cell 
viability or cell proliferation under normal growth conditions. 
Most strikingly, analysis of cell migration, a characteristic impor-
tant for tumor cell invasion, was also unaffected by inhibition of 
autophagy when assayed in 2D. This naturally raises the question © 2012 Landes Bioscience.
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Figure 4. Atg12 knockdown inhibits tumor cell invasion. (A–D) Hematoxylin and eosin-stained sections of GL261 cells on organotypic matrix. GL261 
shAtg12 cells (A and B) and NtC cells (C and D) were seeded on to an organotypic matrix in the absence (A and C) or presence (B and D) of doxycycline. 
Images are shown of GL261 shAtg12 cells and NtC cells after 7 or 9 d of invasion, respectively. (e and F) Quantification of invasion. the average number 
of invading shAtg12 cells (e) and NtC cells (F) in four representative Hematoxylin and eosin-stained images (10x objective lens) were counted for 7 and 
9 d of invasion. Scale bars are 200 μm, and error bars are standard deviations from four different microscope images.© 2012 Landes Bioscience.
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of how cell invasion in our organotypic model is affected by loss 
of autophagy. Ultimately, this may simply reflect differences in 
cell behavior in 2D vs. 3D. For example, it has been reported 
that epithelial-mesenchymal transitions of cells can be different 
upon transfer from 2D to 3D, and that their motility, and there-
fore migratory capacity, can be affected as a result.26-28 Clearly, 
culture in 2D has its limitation and analysis of invasion in the 
organotypic model more accurately reflects the environment 
in which migration and invasion would occur in vivo. In this 
context, tumor cells have a more complex interaction with the 
microenvironment that may reveal and/or invoke the develop-
ment of additional tumor cell characteristics. It may be the case 
that autophagy-competent cells are better at digesting extracel-
lular matrix components either externally, via secretion of pro-
teins such matrix metalloproteases, or internally, via digestion of 
extracellular matrix components in lysosomes, and this may aid 
invasion through the matrix. Equally, autophagy-competent cells 
may respond differently to the availability of extracellular matrix-
derived ligands such as fibronectin or collagen. Finally, it must be 
remembered that culture in our organotypic model involves an 
intricate relationship between tumor cells and fibroblasts. These 
cells in the organotypic model secrete factors to which tumor 
cells can respond in an invasive manner, and it may be the case 
that autophagy-deficient cells are impaired in their response to 
these agents. Moreover, studies have shown that migrating fibro-
blasts can act as “path leaders” for tumor cell invasion, and again, 
autophagy in tumor cells may be required for this process.29
Although the ability to tease out the mechanistic details 
underlying the role of autophagy in invasion is beyond the scope 
of this current study, we feel it is without question that the find-
ings we present here have important implications for our under-
standing of the role of autophagy in cancer. Reports have shown 
that autophagy is required for other tumor-associated traits, and 
we consider that we add to this list by showing that autophagy is 
required for tumor cell invasion. As a result of our data, it is natu-
ral to speculate, as has previously been suggested,30 that autoph-
agy may be required for metastasis, although it not clear whether 
inhibition of autophagy would affect established metastases or 
just the ability to initiate metastasis. Further studies are therefore 
required to address these intriguing issues by analysis of the role 
of autophagy in in vivo models of human cancer.
Materials and Methods
Cell lines and cell culture. Mouse glioblastoma cell line GL261 
was cultured at 37°C under 5% CO2 in a high-humidity atmo-
sphere in Dulbecco’s modified Eagle medium (DMEM, Gibco) 
supplemented with 10% fetal bovine serum (FBS), 2 mM gluta-
mine, 100 U/ml penicillin and 100 μg/ml streptomycin. GL261 
cells expressing pTRIPZ shRNA NTC or ATG12 were supple-
mented with puromycin (0.5 μg/ml). Where indicated, doxycy-
cline (Sigma Aldrich) was used at a concentration of 2 μg/ml. 
E64d and pepstatin A (both from Calbiochem) were both used 
at a concentration of 10 μg/ml.
Construction of inducible shRNA cell line. Mouse pGIPZ-
shATG12mir individual clone (ID V2LMM_72549) was 
purchased from Open Biosystems, and gene knockdown was 
verified. The shRNAmir clone was moved from pGIPZ to the 
pTRIPZ lentiviral inducible system (Open Biosystems) according 
to the manufacturers instructions. Briefly, pGIPZ-shATG12mir 
and pTRIPZ vectors were prepared for ligation by performing 
a MluI/XhoI double digestion. Clones were verified by Sal1 
digestion, and the sequence was verified by using the pTRIPZ 
sequencing primer GGA AAG AAT CAA GGA GG. The 
pTRIPZ empty vector and the non-silencing pTRIPZ lentiviral 
shRNAmir control were also purchased from Open Biosystems. 
The Translentiviral shRNA Packaging System with Arrestin-In 
transfection reagent (Open Biosystems) was used to generate len-
tivirus particles in HEK293FT cells. GL261, murine glioma cell 
line was obtained from NCI-Frederick and were transduced with 
lentivirus using 8 ug/ml polybrene and selected with 1 ug/ ml 
puromycin. Doxyclycine was used at a concentration of 2 ug/ ml 
to induce expression of TurboRFP and ATG12 gene knockdown; 
single clones demonstrating efficient TurboRFP expression upon 
doxycycline treatment were isolated.
Western blotting. Cell lysates were prepared in lysis buffer 
(1% triton-X, 0.1% SDS, 50 mM HEPES pH 7.4, 150 mM NaCl, 
100 mM NaF, 10 mM EDTA, 10 mM Na4P2O7 containing pro-
tease inhibitor cocktail from Roche) and transferred to nitrocel-
lulose or immobulin-P membranes as previously described in 
reference 31. Membranes were probed using standard immunob-
lotting techniques. ATG12 and LC3B antibodies were from Cell 
Signaling, and the Erk2 antibody was a kind gift from Prof. Chris 
Marshall (Ab122, CJ Marshall, Institute of Cancer Research).
Starvation-induced autophagic flux assay. GL261 cells 
were cultured with doxycycline for 72 h to induce expression 
of shRNA. Cells were then washed three times in warm PBS 
and once in warm Earle’s balanced salt solution (EBSS, Sigma 
Aldrich) and incubated in EBSS for 2 or 6 h to induce autophagy. 
Autophagic degradation of LC3II was inhibited by addition of 
lysosomal protease inhibitors E64d and pepstatin A. The inhibi-
tors were added prior to starvation and were included in the star-
vation medium, such that cells were incubated with the inhibitors 
for a total of 7 h. Cell lysates were then analyzed by western blot.
LC3 puncta assay. GL261 cells were seeded on microscope 
coverslips and incubated overnight. Cells were then infected with 
an adenovirus containing LC3 fused to GFP. After 16 h incuba-
tion with the virus, the medium was changed, and the cells were 
incubated for a further 24 h. Autophagy was induced by starving 
the cells in EBSS for 6 h. Cells were then fixed (4% parafor-
maldehyde for 20 min at room temperature) and the coverslips 
mounted on slides using immunofluorescence mounting solution 
(Dako) containing 0.5 μg/ml DAPI. Cells were viewed under a 
60x objective with a 488 nm excitation laser to view GFP-LC3 
positive puncta. The number of cells containing puncta was 
counted for four different microscope views.
Cell proliferation and death assays. GL261 cells were cul-
tured with or without doxycycline for 9 d, and the total cell num-
bers were counted periodically as a measure of cell proliferation. 
As an assessment of necrosis, cells (including floating and adher-
ent cells) that had been incubated in the absence or presence 
of Dox for 9 d were harvested with trypsin and incubated with © 2012 Landes Bioscience.
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propidium iodide to label the permeabilized (necrotic) cells. The 
proportion of PI-positive cells was determined by flow cytometry. 
As an assessment of apoptosis, total cell populations including 
floating and adherent cells were harvested fixed in methanol for 
24 h. After this time, cells were stained with propidium iodide, 
and the population analyzed by flow cytometry for the appear-
ance of cells with sub-G1 DNA content, a reliable measure of 
apoptotic cells.32
Wound-healing assay. Cells were cultured with or with-
out doxycycline for 7 d and then seeded into a 6-well plate and 
incubated overnight. A scratch wound was then made, and the 
wound area was photographed by time lapse microscopy over the 
following 24 h at 20 min intervals. Individual cells were then 
tracked over time using ImageJ software, and the average velocity 
and persistence were calculated (17 cells per 10x objective view, 
3 views per wound).
Organotypic invasion assay. Organotypic matrices compris-
ing primary human fibroblasts embedded in polymerized colla-
gen I were constructed, and invasion experiments were performed 
as described previously in references 17, 21 and 22. Briefly, rat tail 
tendon collagen solution (final protein concentration ~2 mg/ml) 
was extracted from tendons with 0.5 M acetic acid. Subsequently 
~7.5 x 104/ml primary human fibroblasts were mixed with colla-
gen solution (2.5 ml) immediately before it was allowed to set in a 
35 mm dish. Polymerized matrices were detached from the edges 
of the dishes and were allowed to contract for approximately 6 d 
in complete media (DMEM, 10% FCS), until the fibroblasts 
had contracted the matrix to ~1.5 cm diameter. GL261 cells were 
seeded (4 x 104 cells in complete medium) on to the matrix, and 
doxycycline was added where indicated. Cells were allowed to 
attach and grow to confluence for 72 h before the matrix was 
transferred to a raised grid in a 6 cm dish containing complete 
medium. The level of the grid was set to the air/liquid interface, 
resulting in the matrix being fed from below with complete 
media that was changed every day. Cells were then allowed to 
invade toward the culture medium for 7 or 9 d. The organotypic 
matrix was then fixed using 4% paraformaldehyde and processed 
by standard methods for hematoxylin and eosin (H&E) staining. 
Four representative images (10x objective) were taken for each 
organotypic matrix, and the number of GL261 cells that invaded 
past the surface of the matrix were counted as invading cells. 
Representative 20x images were also taken.
Statistical analyses. Statistical significance was determined by 
the Student t-test, and p-values of less than 0.05 were considered 
significant.
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